203641 Sigma-AldrichBMP-2, Human, Recombinant, E. coli
Aperçu
| Replacement Information |
|---|
Tableau de caractéristiques principal
| Purity |
|---|
| ≥95% by SDS-PAGE |
| Product Information | |
|---|---|
| Form | Lyophilized |
| Formulation | Lyophilized from sterile 10 mM sodium citrate, pH 3.5. |
| Quality Level | MQ100 |
| Applications |
|---|
| Biological Information | |
|---|---|
| Purity | ≥95% by SDS-PAGE |
| Physicochemical Information |
|---|
| Dimensions |
|---|
| Materials Information |
|---|
| Toxicological Information |
|---|
| Safety Information according to GHS |
|---|
| Safety Information |
|---|
| Product Usage Statements |
|---|
| Packaging Information |
|---|
| Transport Information |
|---|
| Supplemental Information |
|---|
| Specifications |
|---|
| Global Trade Item Number | |
|---|---|
| Référence | GTIN |
| 203641 | 0 |
Documentation
BMP-2, Human, Recombinant, E. coli FDS
| Titre |
|---|
Références bibliographiques
| Aperçu de la référence bibliographique |
|---|
| Csiszar, A., et al. 2006. Am. J. Pathol. 168, 629. Kumagai, T., et al. 2006. Anticancer Res. 26, 293. Kumagai, T., et al. 2006. Int. J. Mol. Med. 17, 285. Kuo, P.L., et al. 2006. Biol. Pharm. Bull. 29, 119. Morin, R., et al. 2006. Biomacromolecules 7, 131. Villavicencio, A.T., et al. 2005. J. Neurosurg. Spine 3, 436. |



